

**DESCRIPTION**

<b>Source</b>	Chinese Hamster Ovary cell line, CHO-derived human CD160 protein		
	Human CD160 (Ile25-Ser159) Accession # O95971.1	IEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)
	N-terminus		C-terminus
<b>N-terminal Sequence Analysis</b>	Ile25		
<b>Structure / Form</b>	Disulfide-linked homodimer		
<b>Predicted Molecular Mass</b>	41 kDa		



**SPECIFICATIONS**

<b>SDS-PAGE</b>	39-59 kDa, under reducing conditions
<b>Activity</b>	Measured by its binding ability in a functional ELISA. Recombinant Human CD160 Fc Chimera Protein binds to Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein (Catalog # 11177-HV) with an ED <sub>50</sub> of 30.0-300 ng/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 250 µg/mL in sterile water.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**DATA**



**BACKGROUND**

CD160 (also Natural killer cell receptor BY55) is a 27 - 30 kDa member of the Ig superfamily (1 - 4). In human, it is expressed principally on nonmyeloid hematopoietic cells. These include CD56<sup>DIM</sup>CD16+ cytolytic NK cells, CD8+CD28- T cells, CD8+CD101+ IELs, NKT cells,  $\gamma\delta$  TCR T cells, activated CD4+ T cells, and vascular endothelial cells (1, 5 - 7). CD160 was initially identified as a GPI-linked glycoprotein (3). It is synthesized as a preproprotein that is 181 amino acids (aa) in length. The precursor contains a 26 aa signal sequence, a 133 aa mature molecule that shows one 96 aa V-type Ig-like domain (aa 27 - 122), and a 22 aa prosegment that is cleaved to generate a GPI-linkage at Ser159. GPI-linked CD160 is known to be cleaved by phospholipases and these generate an 80 kDa (presumably trimeric) band in SDS-PAGE (1, 8). Alternative splice forms for CD160 are reported to exist on activated NK cells. The principal variant is an extended type I transmembrane (TM) protein that shows a 55 aa substitution for the C-terminal two amino acids. It contains a 23 aa TM segment (aa 160 - 182) and a 52 aa cytoplasmic region. Two other variants show deletions of the Ig-like domain in both the GPI-linked and TM form (9). Mature human CD160 shares 62% aa identity with mouse CD160.

CD160 is known to bind to HLA-G1, HLA-C, and HVEM (6, 9, 10). And upon engagement, it is reported to associate with CD2 in *cis* under certain conditions (11, 12). The effects of CD160 ligation appear to be context dependent. When expressed on endothelial cells, CD160 binding to HLA-G1 initiates apoptosis, and thus impacts angiogenesis (6). When expressed on CD56<sup>DIM</sup> NK cells, CD160 signaling in response to HLA-C binding promotes IFN- $\gamma$ , TNF- $\alpha$ , and IL-6 secretion (10). And when up-regulated on CD4+ T cells following activation, CD160 engagement by HVEM (expressed by APC) serves to block a simultaneous LIGHT stimulation of HVEM that promotes receptor expression and cytokine release (1, 2, 7, 13).

**References:**

1. Cai, G. & G.J. Freeman (2009) *Immunol. Rev.* **229**:244.
2. del Rio, M.L. *et al.* (2010) *J. Leukoc. Biol.* **87**:223.
3. Maiza, H. *et al.* (1993) *J. Exp. Med.* **178**:1121.
4. Anumanthan, A. *et al.* (1998) *J. Immunol.* **161**:2780.
5. Abecassis, S. *et al.* (2007) *J. Invest. Dermatol.* **127**:1161.
6. Fons, P. *et al.* (2006) *Blood* **108**:2608.
7. Kaye, J. *et al.* (2008) *Nat. Immunol.* **9**:122.
8. Giustiniani, J. *et al.* (2007) *J. Immunol.* **178**:1293.
9. Giustiniani, J. *et al.* (2009) *J. Immunol.* **182**:63.
10. Barakonyi, A. *et al.* (2004) *J. Immunol.* **173**:5349.
11. Nikolova, M. *et al.* (2002) *Int. Immunol.* **14**:445.
12. Rabot, M. *et al.* (2006) *Transpl. Immunol.* **17**:36.
13. Cai, G. *et al.* (2008) *Nat. Immunol.* **9**:176.